Stratec SE
XETRA:SBS

Watchlist Manager
Stratec SE Logo
Stratec SE
XETRA:SBS
Watchlist
Price: 30 EUR 0.84%
Market Cap: 364.8m EUR
Have any thoughts about
Stratec SE?
Write Note

Stratec SE
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Stratec SE
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Stratec SE
XETRA:SBS
Cash from Financing Activities
-€4.7m
CAGR 3-Years
41%
CAGR 5-Years
N/A
CAGR 10-Years
5%
Carl Zeiss Meditec AG
XETRA:AFX
Cash from Financing Activities
-€100.1m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Cash from Financing Activities
-€20.4m
CAGR 3-Years
-15%
CAGR 5-Years
-16%
CAGR 10-Years
-24%
Siemens Healthineers AG
XETRA:SHL
Cash from Financing Activities
-€1.6B
CAGR 3-Years
N/A
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Cash from Financing Activities
-€154.3m
CAGR 3-Years
12%
CAGR 5-Years
-30%
CAGR 10-Years
-12%
Sartorius AG
XETRA:SRT
Cash from Financing Activities
-€191.7m
CAGR 3-Years
-13%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
No Stocks Found

Stratec SE
Glance View

Market Cap
364.7m EUR
Industry
Health Care

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

SBS Intrinsic Value
57.63 EUR
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Stratec SE's Cash from Financing Activities?
Cash from Financing Activities
-4.7m EUR

Based on the financial report for Sep 30, 2024, Stratec SE's Cash from Financing Activities amounts to -4.7m EUR.

What is Stratec SE's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
5%

The average annual Cash from Financing Activities growth rates for Stratec SE have been 41% over the past three years , and 5% over the past ten years .

Back to Top